Notice to stakeholders on the draft pause the clock proposal for pre-market submissions and applications

Download PDF

Response to the public consultation on the draft Pause the Clock Proposal for Pre-market Submissions / Applications

Health Canada is pleased to announce the release of the What Was Heard report resulting from the consultation on the draft Pause the Clock Proposal for Pre-market Submissions/Applications. All comments from the 60-day comment period ending October 9, 2018 were reviewed and considered in the finalization of the pause the clock policy.

The following key changes are being made to the pause the clock policy as a result of internal and external stakeholder consultations:


Some respondents requested Health Canada to grant short-term extensions without a pause. For the review clock to pause, the request for an extension to respond to a clarification or minor information request will need to be a minimum of 5 days but not beyond 90 days per clarification request. Any extension beyond 5 days without a pause defeats the purpose of the pause the clock proposal whereby Health Canada is only accountable for the time it spends on a particular submission/application.

Medical Devices:

Some respondents suggested additional triggers that would pause the clock; many of which would fall under the proposed triggers. Implementation of the pause the clock policy will be monitored and the need to modify or add triggers will be assessed over time.

Further, many comments referred to the efficiency and predictability of the review process and changes to penalty provisions. Health Canada is committed to continuing to meet performance standards. Pause the clock is only one tool that is being implemented, along with ongoing measures to improve the efficiency of the submission/application review process.

Introduction of the pause the clock policy is not anticipated to negatively impact aligned reviews, joint reviews, and simultaneous global filings, especially when communicated to collaborating parties.

Comments regarding the acceptance of additional data in a submission once filed were also noted. Although out of scope of this project, this may be looked at under other ongoing/future initiatives.

Several respondents raised questions around the operationalization of the process. The updated policy and additional detail on how it will be operationalized will be communicated in guidance documents that are used by Health Canada and sponsors to navigate the submission/application process, namely:

Updated guidance will be publicly available as Health Canada’s renewed cost recovery framework for drugs and medical devices is implemented.

Contact Information

Office of Policy and International Collaboration
Biologics and Genetic Therapies Directorate
Health Products and Food Branch
Health Canada
Building #6, 100 Eglantine Driveway
Tunney’s Pasture
Ottawa, ON K1A 0K9
Address Locator: 0601B
Fax number: (613) 952-5364

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: